🔎 Trials Near Me

Home › Soft Tissue Sarcoma › Missouri

Soft Tissue Sarcoma clinical trials in Missouri

15 studies for Soft Tissue Sarcoma are looking for participants at sites in Missouri.

Cities in Missouri

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

  • Washington University School of Medicine in St. Louis, St Louis
RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

  • Washington University School of Medicine, St Louis
  • Siteman Cancer Center-South County, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT05711615

Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma

  • Washington University in St. Louis, St Louis
RecruitingPhase 1/2
Ages 12 to 40 · All sexes · Updated Sep 3, 2026 · NCT07725380

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

  • Washington University School of Medicine, St Louis
RecruitingObservational study
Ages 18 to 50 · Women · Updated Sep 2, 2026 · NCT06904365

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
  • Central Care Cancer Center - Bolivar, Bolivar
  • Cox Cancer Center Branson, Branson
  • and 21 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069

IDOV-Immune for Advanced Solid Tumors

  • Washington University School of Medicine, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06910657

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

  • Washington University Medical Center, St Louis
RecruitingPhase 1/2
Up to age 30 · All sexes · Updated Aug 3, 2026 · NCT06239272

Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

  • Washington University in St. Louis, St Louis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 28, 2026 · NCT04040205

Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

  • Zai Lab Site 02005, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT07374848

Lead-212 PSV359 Therapy for Patients With Solid Tumors

  • Saint Louis University, St Louis
RecruitingPhase 1/2
Ages 18 to 90 · All sexes · Updated Jul 6, 2026 · NCT06710756

Integrated Cancer Repository for Cancer Research

  • Saint Luke's Cancer Institute, East, Kansas City
  • Saint Luke's Cancer Institute, Kansas City
  • Saint Luke's Cancer Institute, Kansas City North, Kansas City
  • and 3 more
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699

Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

  • Washington University School of Medicine, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 3, 2026 · NCT06957431

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

  • Washington University Infusion Center Pharmacy, St Louis
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated May 27, 2026 · NCT03093116

Propranolol for the Treatment of Kaposi Sarcoma in Adults

  • Washington University School of Medicine, St Louis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 6, 2026 · NCT06445166

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

  • Washington University School of Medicine, St Louis
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Feb 20, 2026 · NCT04354064

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.